MX2021002971A - Anticuerpos del receptor anti-interleucina 4 para uso veterinario. - Google Patents

Anticuerpos del receptor anti-interleucina 4 para uso veterinario.

Info

Publication number
MX2021002971A
MX2021002971A MX2021002971A MX2021002971A MX2021002971A MX 2021002971 A MX2021002971 A MX 2021002971A MX 2021002971 A MX2021002971 A MX 2021002971A MX 2021002971 A MX2021002971 A MX 2021002971A MX 2021002971 A MX2021002971 A MX 2021002971A
Authority
MX
Mexico
Prior art keywords
antibodies
various embodiments
il4r
receptor antibodies
veterinary use
Prior art date
Application number
MX2021002971A
Other languages
English (en)
Inventor
Shyr Jiann Li
Lam Nguyen
Hangjun Zhan
Richard Chin
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of MX2021002971A publication Critical patent/MX2021002971A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Se proporcionan varias modalidades relacionadas con anticuerpos anti-IL4R que se unen a la IL4R canina; en diversas modalidades, tales anticuerpos anti-IL4R pueden usarse en métodos para tratar afecciones inducidas por IL4/IL13, tales como dermatitis atópica, dermatitis alérgica, prurito, asma, psoriasis, esclerodermia y eccema, en animales de compañía, tales como caninos y felinos; también se proporcionan diversas modalidades relacionadas con polipéptidos IgG Fc variantes y regiones constantes de cadena ligera variantes de especies animales de compañía para la preparación de anticuerpos o anticuerpos biespecíficos.
MX2021002971A 2018-09-14 2019-09-14 Anticuerpos del receptor anti-interleucina 4 para uso veterinario. MX2021002971A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731633P 2018-09-14 2018-09-14
PCT/US2019/051201 WO2020056393A1 (en) 2018-09-14 2019-09-14 Anti-il4 receptor antibodies for veterinary use

Publications (1)

Publication Number Publication Date
MX2021002971A true MX2021002971A (es) 2021-05-12

Family

ID=69778506

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002971A MX2021002971A (es) 2018-09-14 2019-09-14 Anticuerpos del receptor anti-interleucina 4 para uso veterinario.

Country Status (10)

Country Link
US (1) US20220049002A1 (es)
EP (1) EP3849610A4 (es)
JP (2) JP2022500037A (es)
KR (1) KR20210091691A (es)
CN (1) CN113164593A (es)
AU (1) AU2019338602A1 (es)
BR (1) BR112021004723A2 (es)
CA (1) CA3111854A1 (es)
MX (1) MX2021002971A (es)
WO (1) WO2020056393A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
WO2020139984A1 (en) * 2018-12-27 2020-07-02 Kindred Biosciences, Inc. Igg fc variants for veterinary use
BR112021012513A2 (pt) 2019-01-03 2021-09-14 Invetx Inc. Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso
CA3169301A1 (en) * 2020-03-18 2021-09-23 Shyr Jiann Li Anti-il4 receptor antibodies for veterinary use
GB202005879D0 (en) * 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins
EP4149969A1 (en) 2020-05-11 2023-03-22 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
WO2022005883A1 (en) * 2020-06-29 2022-01-06 Zoetis Services Llc Feline antibody variants for improving stability
WO2022010652A1 (en) 2020-07-10 2022-01-13 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944989A1 (en) * 2013-04-08 2014-10-16 Cytodyn Inc. Felinized antibodies and methods of treating retroviral infections in felines
TWI697334B (zh) * 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
EP3148580B1 (en) * 2014-05-29 2021-01-20 MacroGenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
EP3295951B1 (en) * 2015-02-19 2020-04-22 Compugen Ltd. Anti-pvrig antibodies and methods of use
JP6938383B2 (ja) * 2015-04-02 2021-09-22 インターベット インターナショナル ベー． フェー． イヌインターロイキン４受容体アルファに対する抗体
EP3390451A1 (en) * 2015-12-18 2018-10-24 Intervet International B.V. Caninized human antibodies to human and canine il-4ralpha
CN110114369A (zh) * 2016-10-17 2019-08-09 威隆股份公司 修饰的抗体恒定区

Also Published As

Publication number Publication date
EP3849610A4 (en) 2022-12-07
WO2020056393A1 (en) 2020-03-19
AU2019338602A1 (en) 2021-04-01
CN113164593A (zh) 2021-07-23
BR112021004723A2 (pt) 2021-06-08
EP3849610A1 (en) 2021-07-21
JP2024009807A (ja) 2024-01-23
US20220049002A1 (en) 2022-02-17
CA3111854A1 (en) 2020-03-19
KR20210091691A (ko) 2021-07-22
JP2022500037A (ja) 2022-01-04

Similar Documents

Publication Publication Date Title
MX2021002971A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
CY1123791T1 (el) Μονοκλωνικο αντισωμα ιντερλευκινης-31
JOP20200213A1 (ar) جزيئات رابطة لـ pd-1 وطرق استخدامها
MX2021013681A (es) Moleculas de union a lag-3 y metodos de uso de las mismas.
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MX2022011335A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
EA201690325A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ
CR20190009A (es) Anticuerpos anti-pd-1, un método de producción y un método para su uso.
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
AU2018254542A1 (en) IL4/IL13 receptor molecule for veterinary use
EA201791393A3 (ru) Антитела к erbb3 и их применение
MX2016005765A (es) Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos.
EA201990894A9 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
WO2013188448A8 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
EA201991203A1 (ru) Способы лечения ожирения антителами к angptl8
CL2016001028A1 (es) Anticuerpos de alta afinidad y de agregación estable basados en dominios variables de vl y derivados de vhh.
EA201992460A1 (ru) Антитела-агонисты btla и их применение
MX2022014375A (es) Anticuerpo anti-cd20 quimerico canino.
MX2021011335A (es) Antagonistas de ngf para uso medicinal.
MX2022002360A (es) Anticuerpos de anti-il31 para uso veterinario.
EA201891594A1 (ru) Антитела к il-17c
MX2022013149A (es) Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario.
MX2022013147A (es) Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario.
MY188871A (en) Pd-1-binding molecules and methods of use thereof